CYP4F8
Cytochrome P450 Family 4 Subfamily F Member 8
Gene Information Card
| Symbol | CYP4F8 |
|---|---|
| Full Name | Cytochrome P450 Family 4 Subfamily F Member 8 |
| Gene Type | protein-coding |
| Chromosomal Location | 19p13.12 |
| NCBI Gene ID | 11283 ncbi.nlm.nih.gov/gene/11283 |
| Ensembl ID | ENSG00000105426 |
| UniProt ID | P98187 |
| OMIM ID | 611545 |
| HGNC ID | 2646 |
| Aliases | CYPIVF8 |
Description
CYP4F8 is a member of the cytochrome P450 superfamily of enzymes, specifically the CYP4F subfamily. The encoded protein is a monooxygenase that catalyzes the omega-hydroxylation of prostaglandins and other eicosanoids, playing a role in the metabolism of arachidonic acid derivatives. It is primarily expressed in the liver, kidney, and prostate.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Prostate cancer | Altered eicosanoid metabolism may influence tumor progression; CYP4F8 expression is upregulated in prostate cancer tissues. | PMID: 14559847 |
| Essential hypertension | Polymorphisms in CYP4F8 may affect renal eicosanoid metabolism and blood pressure regulation. | PMID: 16966485 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Liver | 5.2 | Low |
| Kidney | 3.8 | Low |
| Prostate | 2.1 | Low |
| Small intestine | 1.5 | Not detected |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HepG2 | 4.0 | Hepatocellular carcinoma cell line |
| LNCaP | 3.5 | Prostate cancer cell line |
| HEK293 | 1.2 | Embryonic kidney cell line |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| rs11187838 | SNP | 0.15 (global) | Missense variant (p.Val433Ile); functional impact unknown |
| rs2108622 | SNP | 0.08 (global) | Intronic variant; associated with hypertension in some studies |
Mutation functional classification
Loss of Function (LOF)
No confirmed loss-of-function mutations reported in major databases.
Gain of Function (GOF)
No confirmed gain-of-function mutations reported.
Dominant Negative (DN)
No dominant-negative mutations described.
View complete mutation data：
Gene Ontology (GO)
| • arachidonic acid monooxygenase activity | • heme binding |
| • iron ion binding | • oxidoreductase activity |
| • acting on paired donors | • with incorporation or reduction of molecular oxygen |
| • omega-hydroxylase activity |
Pathways
• Arachidonic acid metabolism
• Prostaglandin synthesis and regulation
Protein Summary
The CYP4F8 protein is a 520-amino acid microsomal cytochrome P450 that catalyzes the omega-hydroxylation of prostaglandins (e.g., PGE2, PGF2α) and other eicosanoids. It is involved in the inactivation of these signaling molecules, thereby modulating inflammatory and vascular responses. The protein is localized to the endoplasmic reticulum and is expressed in liver, kidney, and prostate tissues.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| CYP4F8 Knockout HEK293 Cell Line | EDJ-KQ7363 | Human | 11283 | Details Get a Quote |
| CYP4F8 Knockout HeLa Cell Line | EDJ-KQ55626 | Human | 11283 | Details Get a Quote |
| CYP4F8 Knockout A-549 Cell Line | EDJ-KQ64125 | Human | 11283 | Details Get a Quote |
| CYP4F8 Knockout HCT 116 Cell Line | EDJ-KQ72569 | Human | 11283 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
